Major cardiac events not more common in patients receiving JAK inhibitors vs adalimumab

The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.
“Embolism and venous thromboembolism events (VTEs) and major adverse cardiovascular events (MACEs) have raised concerns among patients with rheumatoid arthritis (RA) receiving a Janus kinase inhibitor (JAKi) (both tofacitinib [Xeljanz, Pfizer] and baricitinib [Olumiant, Eli Lilly]),” Lea Hoisnard, MD, of the University hospital of Henri-Mondor, in Créteil, France,

The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.
“Embolism and venous thromboembolism events (VTEs) and major adverse cardiovascular events (MACEs) have raised concerns among patients with rheumatoid arthritis (RA) receiving a Janus kinase inhibitor (JAKi) (both tofacitinib [Xeljanz, Pfizer] and baricitinib [Olumiant, Eli Lilly]),” Lea Hoisnard, MD, of the University hospital of Henri-Mondor, in Créteil, France,